Antimicrobial considerations in anaerobic infections.
D000193:Actinomycetales Infections / Q000188:drug therapy; D000693:Anaerobiosis; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D001442:Bacteroides Infections / Q000188:drug therapy; D002511:Cephalosporins / Q000627:therapeutic use; D002701:Chloramphenicol / Q000627:therapeutic use; D002981:Clindamycin / Q000627:therapeutic use; D003015:Clostridium Infections / Q000188:drug therapy; D004917:Erythromycin / Q000627:therapeutic use; D005673:Fusobacterium; D006801:Humans; D008034:Lincomycin / Q000627:therapeutic use; D008795:Metronidazole / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D010100:Oxygen; D010406:Penicillins / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D013290:Streptococcal Infections / Q000188:drug therapy; D013752:Tetracycline / Q000627:therapeutic use; D014211:Treponemal Infections / Q000188:drug therapy; D014640:Vancomycin / Q000627:therapeutic use; D014678:Veillonella
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D010406:Penicillins; D008795:Metronidazole; D002981:Clindamycin; D004917:Erythromycin; D002701:Chloramphenicol; D014640:Vancomycin; D008034:Lincomycin; D013752:Tetracycline; D010100:Oxygen; D012293:Rifampin